Triasima Portfolio Management inc. Buys Shares of 3,361 Cencora, Inc. $COR

Triasima Portfolio Management inc. acquired a new position in Cencora, Inc. (NYSE:COR) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 3,361 shares of the company’s stock, valued at approximately $1,050,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. UMB Bank n.a. grew its position in Cencora by 6.9% in the second quarter. UMB Bank n.a. now owns 1,558 shares of the company’s stock worth $467,000 after acquiring an additional 101 shares in the last quarter. Farther Finance Advisors LLC boosted its position in shares of Cencora by 107.4% during the 2nd quarter. Farther Finance Advisors LLC now owns 4,512 shares of the company’s stock valued at $1,353,000 after acquiring an additional 2,337 shares in the last quarter. Park Avenue Securities LLC raised its holdings in shares of Cencora by 19.8% in the 2nd quarter. Park Avenue Securities LLC now owns 15,186 shares of the company’s stock worth $4,553,000 after buying an additional 2,507 shares in the last quarter. U.S. Capital Wealth Advisors LLC lifted its holdings in shares of Cencora by 0.4% during the second quarter. U.S. Capital Wealth Advisors LLC now owns 8,547 shares of the company’s stock valued at $2,563,000 after acquiring an additional 38 shares during the period. Finally, ABLE Financial Group LLC bought a new stake in Cencora during the second quarter worth about $211,000. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts recently weighed in on COR shares. JPMorgan Chase & Co. increased their price objective on shares of Cencora from $344.00 to $417.00 and gave the company an “overweight” rating in a report on Tuesday, November 11th. Barclays initiated coverage on shares of Cencora in a research note on Monday, December 8th. They issued an “overweight” rating and a $400.00 target price for the company. Robert W. Baird set a $415.00 price target on shares of Cencora in a research note on Tuesday, January 13th. TD Cowen boosted their price objective on shares of Cencora from $350.00 to $400.00 and gave the company a “buy” rating in a report on Monday, November 10th. Finally, Wall Street Zen cut shares of Cencora from a “buy” rating to a “hold” rating in a research note on Friday, November 28th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $381.42.

Cencora Trading Up 0.3%

Shares of COR opened at $355.86 on Tuesday. The business’s 50-day moving average price is $349.45 and its 200-day moving average price is $320.73. The company has a quick ratio of 0.55, a current ratio of 0.90 and a debt-to-equity ratio of 4.32. The stock has a market cap of $69.03 billion, a PE ratio of 44.86, a P/E/G ratio of 1.69 and a beta of 0.66. Cencora, Inc. has a twelve month low of $237.71 and a twelve month high of $377.54.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.79 by $0.05. Cencora had a return on equity of 227.15% and a net margin of 0.48%.The firm had revenue of $83.73 billion for the quarter, compared to analysts’ expectations of $83.36 billion. During the same period last year, the firm earned $3.34 earnings per share. The company’s revenue for the quarter was up 5.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. On average, equities analysts forecast that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, December 1st. Shareholders of record on Friday, November 14th were given a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a yield of 0.7%. This is a boost from Cencora’s previous quarterly dividend of $0.55. The ex-dividend date was Friday, November 14th. Cencora’s dividend payout ratio (DPR) is currently 30.19%.

Insider Activity

In other Cencora news, EVP Elizabeth S. Campbell sold 3,351 shares of the company’s stock in a transaction on Friday, December 19th. The stock was sold at an average price of $342.10, for a total value of $1,146,377.10. Following the completion of the sale, the executive vice president directly owned 23,891 shares in the company, valued at approximately $8,173,111.10. This represents a 12.30% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Silvana Battaglia sold 1,677 shares of the firm’s stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $345.00, for a total transaction of $578,565.00. Following the completion of the sale, the executive vice president owned 18,796 shares in the company, valued at $6,484,620. This represents a 8.19% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 15,220 shares of company stock valued at $5,343,561. 10.80% of the stock is currently owned by company insiders.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.